Details for New Drug Application (NDA): 209659
✉ Email this page to a colleague
The generic ingredient in BORTEZOMIB is bortezomib. There are twenty drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the bortezomib profile page.
Summary for 209659
| Tradename: | BORTEZOMIB |
| Applicant: | Fresenius Kabi Usa |
| Ingredient: | bortezomib |
| Patents: | 0 |
Pharmacology for NDA: 209659
| Mechanism of Action | Proteasome Inhibitors |
Medical Subject Heading (MeSH) Categories for 209659
Suppliers and Packaging for NDA: 209659
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| BORTEZOMIB | bortezomib | INJECTABLE;INTRAVENOUS, SUBCUTANEOUS | 209659 | ANDA | Fresenius Kabi USA, LLC | 63323-821 | 63323-821-10 | 1 VIAL, SINGLE-USE in 1 CARTON (63323-821-10) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, SINGLE-USE |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | INJECTABLE;INTRAVENOUS, SUBCUTANEOUS | Strength | 3.5MG/VIAL | ||||
| Approval Date: | May 2, 2022 | TE: | AP | RLD: | No | ||||
Complete Access Available with Subscription
